Key result
Valve-in-valve TAVR treats bioprosthetic degeneration despite higher risks of coronary obstruction and patient-prosthesis mismatch.
Why the study?
Aortic valve-in-valve implantation is technically more challenging than native TAVR, with main challenges including higher risks of coronary obstruction, severe patient-prosthesis mismatch, and difficult coronary re-access.
Population
Patients affected by bioprosthetic heart valve degeneration
Comparison
Trans-catheter aortic valve-in-valve implantation
Design
Review
Authors
Loading...
Multimodal imaging supports ViV planning; leaves open standardized, valve-specific protocols.
This review highlights the principles, multimodal imaging requirements, and specific procedural challenges of valve-in-valve TAVR for degenerated aortic bioprostheses.
Buono et al. (2022) conducted a review in Bioprosthetic heart valve (BHV) degeneration. Valve-in-valve (ViV) trans-catheter aortic valve replacement (TAVR) was evaluated. Valve-in-valve TAVR is a valid treatment for bioprosthetic heart valve degeneration, though it carries challenges such as higher risk of coronary obstruction and patient-prosthesis mismatch.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: